Pelareorep

Oncolytics Biotech® Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing Cohort

Retrieved on: 
Thursday, March 24, 2022
Company, Cancer, Cell, Business development, NASDAQ, Forward-looking statement, Death, Growth, Clinical trial, Biotechnology, Research, PIK3CA, Woman, Neoplasm, PBMC, Tissue, Lymphatic system, Chinese Medical Journal, TSX, Roche, Travel, Safety, EP4, Paclitaxel, Securities Exchange Act of 1934, Pelareorep, Time, AB, COVID-19, Breast cancer, Regulation, Phenotype, Breast Cancer Research Foundation, SAN, FDA, Patient, Partnership, ONC, Pharmaceutical industry, Medical imaging, Oncolytics Biotech

SAN DIEGO, Calif. and CALGARY, AB, March 24, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that its partner Adlai Nortye has advanced to the third and final dose escalation cohort of the bridging clinical trial evaluating the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced or metastatic breast cancer. The trial's first two cohorts have completed their dose escalation evaluation periods and indicated pelareorep in combination with paclitaxel was well-tolerated with no new safety signals observed to date.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced that its partner Adlai Nortye has advanced to the third and final dose escalation cohort of the bridging clinical trial evaluating the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced or metastatic breast cancer.
  • The dosing regimens for the bridging trial's second and third cohorts are equivalent to those administered in Oncolytics' randomized North American breast cancer trials, IND-213 and BRACELET-1, respectively.
  • In IND-213, HR+/HER2- breast cancer patients treated with pelareorep and paclitaxel showed a statistically significant, near doubling of overall survival compared to those treated with paclitaxel alone.
  • "With the bridging trial entering its final cohort less than six months after dosing began, Adlai is making major strides towards satisfying the regulatory criteria needed to accelerate pelareorep's development in China.

Oncolytics Biotech® Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing Cohort

Retrieved on: 
Thursday, March 24, 2022
Company, Cancer, Cell, Business development, NASDAQ, Forward-looking statement, Death, Growth, Clinical trial, Biotechnology, Research, PIK3CA, Woman, Neoplasm, PBMC, Tissue, Lymphatic system, Chinese Medical Journal, TSX, Roche, Travel, Safety, EP4, Paclitaxel, Securities Exchange Act of 1934, Pelareorep, Time, AB, COVID-19, Breast cancer, Regulation, Phenotype, Breast Cancer Research Foundation, SAN, FDA, Patient, Partnership, ONC, Pharmaceutical industry, Medical imaging, Oncolytics Biotech

SAN DIEGO, Calif. and CALGARY, AB, March 24, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that its partner Adlai Nortye has advanced to the third and final dose escalation cohort of the bridging clinical trial evaluating the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced or metastatic breast cancer. The trial's first two cohorts have completed their dose escalation evaluation periods and indicated pelareorep in combination with paclitaxel was well-tolerated with no new safety signals observed to date.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced that its partner Adlai Nortye has advanced to the third and final dose escalation cohort of the bridging clinical trial evaluating the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced or metastatic breast cancer.
  • The dosing regimens for the bridging trial's second and third cohorts are equivalent to those administered in Oncolytics' randomized North American breast cancer trials, IND-213 and BRACELET-1, respectively.
  • In IND-213, HR+/HER2- breast cancer patients treated with pelareorep and paclitaxel showed a statistically significant, near doubling of overall survival compared to those treated with paclitaxel alone.
  • "With the bridging trial entering its final cohort less than six months after dosing began, Adlai is making major strides towards satisfying the regulatory criteria needed to accelerate pelareorep's development in China.

Oncolytics Biotech® Announces Publication of Preclinical and Patient Data Demonstrating Pelareorep's Stimulation of Natural Killer Cell Anti-Cancer Activity

Retrieved on: 
Thursday, March 17, 2022
Liver disease, Trial of the century, ONC, Time, Phenotype, Oncolytic virus, Technology, University, Breast cancer, Patient, AB, Cancer Research UK, NK, Paper, COVID-19, Regulation, Lymphatic system, Institute, Forward-looking statement, Neoplasm, Colorectal cancer, NASDAQ, Clinical trial, Company, Research, Travel, Cancer, Securities Exchange Act of 1934, Pelareorep, Biotechnology, TSX, Immunology, SAN, Natural killer T cell, Pharmaceutical industry, Vaccine, Oncolytics Biotech

(NASDAQ: ONCY) (TSX: ONC) today announced the publication of preclinical and patient data on pelareorep in the peer-reviewed journal Immunology.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced the publication of preclinical and patient data on pelareorep in the peer-reviewed journal Immunology.
  • Results showed pelareorep treatment led to the activation of NK cells, which are known to directly kill cancer cells while stimulating adaptive anti-tumor immunity.
  • Patient samples evaluated in the publication were from a completed window-of-opportunity clinical study evaluating pelareorep in colorectal cancer patients with liver metastases.
  • The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

Oncolytics Biotech® Announces Publication of Preclinical and Patient Data Demonstrating Pelareorep's Stimulation of Natural Killer Cell Anti-Cancer Activity

Retrieved on: 
Thursday, March 17, 2022
Liver disease, Trial of the century, ONC, Time, Phenotype, Oncolytic virus, Technology, University, Breast cancer, Patient, AB, Cancer Research UK, NK, Paper, COVID-19, Regulation, Lymphatic system, Institute, Forward-looking statement, Neoplasm, Colorectal cancer, NASDAQ, Clinical trial, Company, Research, Travel, Cancer, Securities Exchange Act of 1934, Pelareorep, Biotechnology, TSX, Immunology, SAN, Natural killer T cell, Pharmaceutical industry, Vaccine, Oncolytics Biotech

SAN DIEGO and CALGARY, AB, March 17, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of preclinical and patient data on pelareorep in the peer-reviewed journal Immunology. The paper, entitled "Oncolytic virus treatment differentially affects the CD56dim and CD56bright NK cell subsets in vivo and regulates a spectrum of human NK cell activity," was published in collaboration with researchers at several prestigious institutions, including the University of Leeds School of Medicine and the Institute of Cancer Research, London. A link to the paper can be found by clicking here.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced the publication of preclinical and patient data on pelareorep in the peer-reviewed journal Immunology.
  • Results showed pelareorep treatment led to the activation of NK cells, which are known to directly kill cancer cells while stimulating adaptive anti-tumor immunity.
  • Patient samples evaluated in the publication were from a completed window-of-opportunity clinical study evaluating pelareorep in colorectal cancer patients with liver metastases.
  • The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

Oncolytics Biotech® Announces Phase 1b Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Proteasome Inhibitor Combination in Multiple Myeloma in an Abstract at the AACR Annual Meeting

Retrieved on: 
Wednesday, March 9, 2022
NASDAQ, Time, Phenotype, AACR, Multiple myeloma, Bortezomib, Clinical trial, Ernest, University, Company, Research, Lymphatic system, Annual general meeting, Principal, Carfilzomib, Tumor microenvironment, National Cancer Institute, ClinicalTrials.gov, Securities Exchange Act of 1934, Cancer, Regulation, Keck School of Medicine of USC, Medicine, Pelareorep, PFS, Patient, Neoplasm, American Association, AB, ONC, Progression-free survival, TSX, COVID-19, Bristol Myers Squibb, NK, Nivolumab, Association, Poster, Biotechnology, Forward-looking statement, SAN, Travel, Associate, American Association for Cancer Research, Pharmaceutical industry, Oncolytics Biotech

SAN DIEGO, Calif. and CALGARY, AB, March 9, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced phase 1b data demonstrating clinical proof-of-concept for pelareorep-proteasome inhibitor combination therapy in multiple myeloma. The data are featured in an abstract accepted for a poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, which is taking place both virtually and in-person April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The abstract is also posted on the AACR meeting website.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced phase 1b data demonstrating clinical proof-of-concept for pelareorep-proteasome inhibitor combination therapy in multiple myeloma.
  • The AACR data are from a completed phase 1b trial evaluating the combination of pelareorep and the proteasome inhibitor bortezomib in relapsed/refractory multiple myeloma patients.
  • I look forward to discussing these findings with the clinical community and presenting additional data from the trial at the upcoming AACR meeting."
  • Oncolytics continues to build on data from the completed multiple myeloma trial through the advancement of two ongoing phase 1 trials of pelareorep in this indication.

Oncolytics Biotech® Announces Phase 1b Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Proteasome Inhibitor Combination in Multiple Myeloma in an Abstract at the AACR Annual Meeting

Retrieved on: 
Wednesday, March 9, 2022
NASDAQ, Time, Phenotype, AACR, Multiple myeloma, Bortezomib, Clinical trial, Ernest, University, Company, Research, Lymphatic system, Annual general meeting, Principal, Carfilzomib, Tumor microenvironment, National Cancer Institute, ClinicalTrials.gov, Securities Exchange Act of 1934, Cancer, Regulation, Keck School of Medicine of USC, Medicine, Pelareorep, PFS, Patient, Neoplasm, American Association, AB, ONC, Progression-free survival, TSX, COVID-19, Bristol Myers Squibb, NK, Nivolumab, Association, Poster, Biotechnology, Forward-looking statement, SAN, Travel, Associate, American Association for Cancer Research, Pharmaceutical industry, Oncolytics Biotech

SAN DIEGO, Calif. and CALGARY, AB, March 9, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced phase 1b data demonstrating clinical proof-of-concept for pelareorep-proteasome inhibitor combination therapy in multiple myeloma. The data are featured in an abstract accepted for a poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, which is taking place both virtually and in-person April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The abstract is also posted on the AACR meeting website.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced phase 1b data demonstrating clinical proof-of-concept for pelareorep-proteasome inhibitor combination therapy in multiple myeloma.
  • The AACR data are from a completed phase 1b trial evaluating the combination of pelareorep and the proteasome inhibitor bortezomib in relapsed/refractory multiple myeloma patients.
  • I look forward to discussing these findings with the clinical community and presenting additional data from the trial at the upcoming AACR meeting."
  • Oncolytics continues to build on data from the completed multiple myeloma trial through the advancement of two ongoing phase 1 trials of pelareorep in this indication.

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights

Retrieved on: 
Thursday, March 3, 2022
Oncolytics Biotech, Associate, IRENE, PD, Progression-free survival, TSX, Patient, CEACAM6, PD-L1, Data, Breast, AB, GlaxoSmithKline, Society, Breast cancer, Safety, Roche, Halozyme, CD8, Saint Louis University School of Medicine, Pancreatic cancer, International, PR, Survival, LINK, Company, Inflammation, TNBC, Data monitoring committee, Investor relations, Triple-negative breast cancer, Neoplasm, Pelareorep, KRAS, DSMB, Letrozole, Anal cancer, AIO, Translational medicine, Poster, NASDAQ, ONC, Online gambling, Pharmaceutical industry, Medical imaging, Lithium

(NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the quarter and year ended December 31, 2021.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the quarter and year ended December 31, 2021.
  • Dr. Coffey continued, "Our efforts to advance towards our 2022 milestones are built upon the progress we made in 2021.
  • The net loss for the fourth quarter of 2021 was $7.8 million, compared to a net loss of $9.3 million in the fourth quarter of 2020.
  • The basic and diluted loss per share was $0.14 in the fourth quarter of 2021, compared to a basic and diluted loss per share of $0.21 in the fourth quarter of 2020.

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights

Retrieved on: 
Thursday, March 3, 2022
Oncolytics Biotech, Associate, IRENE, PD, Progression-free survival, TSX, Patient, CEACAM6, PD-L1, Data, Breast, AB, GlaxoSmithKline, Society, Breast cancer, Safety, Roche, Halozyme, CD8, Saint Louis University School of Medicine, Pancreatic cancer, International, PR, Survival, LINK, Company, Inflammation, TNBC, Data monitoring committee, Investor relations, Triple-negative breast cancer, Neoplasm, Pelareorep, KRAS, DSMB, Letrozole, Anal cancer, AIO, Translational medicine, Poster, NASDAQ, ONC, Online gambling, Pharmaceutical industry, Medical imaging, Lithium

(NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the quarter and year ended December 31, 2021.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the quarter and year ended December 31, 2021.
  • Dr. Coffey continued, "Our efforts to advance towards our 2022 milestones are built upon the progress we made in 2021.
  • The net loss for the fourth quarter of 2021 was $7.8 million, compared to a net loss of $9.3 million in the fourth quarter of 2020.
  • The basic and diluted loss per share was $0.14 in the fourth quarter of 2021, compared to a basic and diluted loss per share of $0.21 in the fourth quarter of 2020.

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Retrieved on: 
Tuesday, February 22, 2022
TSX, AB, Webcast, Neoplasm, International, Securities Exchange Act of 1934, NASDAQ, COVID-19, Company, Pelareorep, Clinical trial, Regulation, Cancer, Lymphatic system, Travel, ONC, Biotechnology, SAN, Phenotype, Forward-looking statement, Investor relations, Research, Time, Pharmaceutical industry, Oncolytics Biotech

(NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Thursday, March 3, 2022, at 5:00 p.m.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Thursday, March 3, 2022, at 5:00 p.m.
  • ET to discuss a corporate update and financial results for the fourth quarter and full year 2021.
  • Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements.
  • The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Retrieved on: 
Tuesday, February 22, 2022
TSX, AB, Webcast, Neoplasm, International, Securities Exchange Act of 1934, Conference call, NASDAQ, COVID-19, Company, Pelareorep, Clinical trial, Regulation, Cancer, Lymphatic system, Travel, ONC, Biotechnology, Phenotype, Forward-looking statement, Investor relations, Research, Time, Pharmaceutical industry, Oncolytics Biotech, Conference

SAN DIEGO, Calif.  and CALGARY, AB, Feb. 22, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Thursday, March 3, 2022, at 5:00 p.m. ET to discuss a corporate update and financial results for the fourth quarter and full year 2021.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Thursday, March 3, 2022, at 5:00 p.m.
  • ET to discuss a corporate update and financial results for the fourth quarter and full year 2021.
  • Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements.
  • The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.